Recombinant Mouse BTNL9 Fc Chimera Protein, CF

Recombinant Mouse BTNL9 Fc Chimera (Catalog #9555‑BT) inhibits IL-2 secretion by mouse T cellsin the presence of anti-CD antibody. The ED50 for thiseffect is 0.75‑4.5 μg/mL.

• Reactivity: Mu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Mouse BTNL9 Fc Chimera Protein, CF Summary

• Details of Functionality: Measured by its ability to inhibit IL-2 secretion by mouse T cells in the presence of anti-CD3. The ED₅₀ for this effect is 0.75-4.5 μg/mL.
• Source: Mouse myeloma cell line, NS0-derived mouse BTNL9 protein
  

  Mouse BTNL9 (Asp36-Lys257) Accession # Q8BJE2-1	IEGRMDP	Mouse IgG2a (Glu98-Lys330)
  N-terminus		C-terminus

• Accession #: Q8BJE2-1
• N-terminal Sequence: Asp36
• Structure / Form: Disulfide-linked homodimer
• Protein/Peptide Type: Recombinant Proteins
• Purity: >90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Purity Statement: Antigen Affinity-purified
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 52 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 60-73 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 200 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Mouse BTNL9 Fc Chimera Protein, CF

• BTN3
• BTNL9
• butyrophilin 3
• butyrophilin-like 9
• butyrophilin-like protein 9
• UNQ1900/PRO4346
• VDLS1900

Background

Butyrophilin-like 9 (BTNL9) is a member of the BTN/MOG Ig-superfamily and functions as a negative regulator of immune cell activation (1). Mouse BTNL9 is a 536 amino acid (aa) type I transmembrane glycoprotein that contains a 35 aa signal sequence, a 222 aa extracellular domain (ECD), a 21 aa transmembrane region and a 258 aa cytoplasmic segment. The ECD features two V-type Ig-like domains and three glycosylation sites (2-4). The ECD of mouse BTNL9 shares ~67% and 91% aa sequence identity with the ECD of human and rat BTNL9, respectively. BTNL9 is expressed in a variety of tissues in humans and mice. Among isolated immune cell types, B cells show the strongest expression (2, 5). Recombinant BTNL9–Fc has been shown to bind to many immune cells including T cells, B cells, macrophages and dendritic cells (6). With this profile of binding, it will not be surprising if BTNL9 joined the panel of butyrophilins with negative regulatory effects on immune cells (5). BTNL9 has been reported to inhibit CD8⁺ T Cell proliferation (5).

1. Arnett, H.A. et al. (2007) J. Immunol. 178:1523
2. Arnett, H.A. et al. (2009) Cytokine 46:370.
3. Chapoval, A.I. et al. (2013) Mol. Immunol. 56:819.
4. Abeler-Dorner, L. et al. (2012) Trends Immunol. 33:34.
5. Arnett, H.A. et al. (2014) Nat Rev Immunol. 14:5596.
6. Yamazaki, T. et al. (2010) J. Immunol. 185:5907.

Bioinformatics

• Uniprot:
  • Q8BJE2-1()